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ABSTRACT
The RAS-related signalling cascade has a fundamental role in cell. It activates 
differentiation and survival. It is particularly important one of its molecules, B-RAF. 
B-RAF has been a central point for research, especially in melanoma. Indeed, it lacked 
effective therapeutic weapons since the early years of its study. Molecules targeting 
B-RAF have been developed. Nowadays, two classes of molecules are approved 
by FDA. Multi-target molecules, such as Sorafenib and Regorafenib, and selective 
molecules, such as Vemurafenib and Dabrafenib. Many other molecules are still under 
investigation. Most of them are studied in phase 1 trials. Clinical studies correlate 
B-RAF inhibitors and QT prolongation. Though this cardiovascular side effect is not 
common using these drugs, it must be noticed early and recognize its signals. Indeed, 
Oncologists and Cardiologists should work in cooperation to prevent lethal events, 
such as fatal arrhythmias or sudden cardiac death. These events could originate from 
an uncontrolled QT prolongation.
INTRODUCTION
Over the years the development of more and more 
advanced technology, applied in molecular biology, has 
led to the production of new molecules and an increasing 
use of targeted therapies. These molecules can selectively 
inhibit the related targets. Researchers studied extensively 
those targets involved in the cellular signalling pathway 
RAS-RAF-MEK-ERK.
RAF and its isoforms, especially the serine/
threonine kinase BRAF, are commonly activated by 
somatic point mutations in human cancers. BRAF 
mutations are frequently observed in melanoma and in 
colorectal cancer. Activating mutations in BRAF up-
regulate the downstream signalling pathway. This event 
stimulates neoplastic cell proliferation and decreases 
apoptosis [1, 2].
Throughout the years, multi-target drugs inhibiting 
either only BRAF or including BRAF have been 
developed. In this review, we discuss about those drugs 
suppressing BRAF, which have been approved by the 
FDA. They are sorafenib (2005), vemurafenib (2011), 
regorafenib (2012) and dabrafenib (2013). Besides, we 
discuss about other drugs in development, which have not 
yet been approved (Table 1).
MECHANISM OF ACTION OF BRAF 
INHIBITORS
RAS is a proto-oncogene. Its product is a small 
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GTPase, which interchanges the active GTP-bound state 
with the inactive GDP-bound state. It is the starting point 
of a pathway that transmits mitogenic signals from the 
plasma membrane to the nucleus. So, it stimulates cell 
differentiation and survival. The RAS family includes 
H-RAS, N-RAS and K-RAS proteins. Activating 
mutations of specific codons in these clinically relevant 
isoforms of RAS determine malignant transformation. 
They are present in a variety of human cancers. These 
RAS proteins are activated by growth factor receptors 
and stimulate their ultimate effectors through various 
signalling pathways. The most important pathways are the 
RAF/MEK/ERK pathway and the phosphatidylinositol-3-
kinase (PI3K)/PTEN/Akt pathway.
The first signal transduction pathway is also called 
the MAPK cascade. The RAF kinases and their effectors, 
MEK and ERK kinases, stimulate cell proliferation or 
differentiation in relation to the intensity and time duration 
of the signal. RAF serine/threonine kinase has various 
isoforms, which include ARAF, BRAF, and CRAF, also 
called Raf-1. RAF kinases interact with the GTP-bound 
RAS, leading to the RAF protein kinase activation. 
The activated RAF phosphorylates and stimulates the 
kinase MEK, which in turn phosphorylates and activates 
the kinase ERK. This sequence of events triggers 
transcriptional regulators that activate a wide variety of 
cellular phenomena, such as cell cycle progression and 
cell proliferation [3-7].
The second signal transduction pathway, PI3K/
PTEN/Akt, stimulates survival. PI3K is a heterodimeric 
protein with a regulatory subunit, p85, and a catalytic 
subunit, p110. When p85 binds other molecules, it is 
released by the inhibition of p110. PI3K localizes to the 
plasma membrane and it phosphorylates its substrate, 
phosphatidylinositol 4,5-bisphosphate (PI[4,5]P2) on 
the 3’OH position to produce PI(3,4,5)P3. PI(3,4,5)
P3 drags close to it, phosphoinositide-dependent kinase 
1(PDK1) and Akt. PDK1 activates Akt by phosphorylating 
it at threonine 308. After activation, Akt leaves the cell 
membrane to phosphorylate intracellular substrates. 
Besides, it translocates to the nucleus where it stimulates 
several transcriptional regulators, including CREB, E2F 
and nuclear factor κB (NF-κB). NF-κB is localized in the 
cytosol constitutively linked to the inhibitory κ B protein 
kinase (IκB). Under activation NF-κB is translocated to 
the nucleus, where it stimulates the expression of several 
target genes, inducing cell proliferation, invasion and 
inflammation. Akt is involved in cell cycle progression 
and migration, survival, senescence, invasion, metastasis, 
drug resistance and DNA damage repair [8-15]. These two 
Figure 1: Hypotheses for the effects of BRAF inhibitors on cardiomyocyte.
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signal transduction pathways can interact between them 
and with other pathways.
BRAF mutations are frequently detectable in 
melanoma (50-60% of cases), papillary thyroid cancer 
(40-60%), colorectal cancer (about 5-10%), pilocytic 
astrocytoma (10-15%) and non-small-cell lung cancer 
(NSCLC; 3-5%). They are also present in low percentage 
in sarcoma, ovarian carcinoma, breast cancer and liver 
cancer. The six most frequent BRAF mutations are 
V600E, V600K, V600R, V600E2, V600D, and K601E. 
They are about the 95% of all BRAF mutations (COSMIC 
database). Among these, the most common BRAF 
mutation is a T1799A transversion mutation in exon 15, 
which has been discovered in more than 90% of BRAF-
Table 1: Overview of the BRAF inhibitors including those already approved by FDA and those yet in development
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mutant tumors. This mutation determines a substitution 
from the amino acid valine to glutamic acid within the 
activation segment of the kinase. It is also called V600E. 
In addition, the T1799A alteration can even be associated 
with a second nucleotide mutation, G1798A. It leads to 
a V600K mutation. This mutation entails a constitutional 
activation of the kinase protein. So, BRAF targeting may 
be an incisive therapeutic tool for BRAF mutated patients. 
The aim of BRAF inhibitors is to suppress the hyper-
activation of the signalling pathway given by the mutation 
of BRAF, limiting the excessive cell proliferation and 
balancing proliferation and apoptosis [2, 16-19].
CARDIOTOXICITY OF BRAF INHIBITORS
Sorafenib
To date, Sorafenib has been approved by the 
FDA for the treatment of patients with unresectable 
hepatocellular carcinoma (HCC), patients with advanced/
metastatic renal cell carcinoma (RCC) and patients with 
locally recurrent or metastatic, progressive, differentiated 
thyroid carcinoma (DTC) which is refractory to radioactive 
iodine treatment. It is an oral drug. It inhibits multiple 
intracellular and cell surface kinases including VEGFR-2, 
VEGFR-3, RET (including RET/PTC), CRAF, BRAF and 
its mutant forms (including BRAFV600E), c-KIT, FLT-3 and 
platelet-derived growth factor receptor β (PDGFR-β).
There are three main phase 3 trials, which studied 
sorafenib in patients with advanced HCC, SHARP and 
Asia-Pacific trial, and unresectable and/or metastatic 
RCC, TARGET trial. These studies showed that among 
the several side effects, sorafenib gives a certain level 
of cardiotoxicity, mainly hypertension. In the SHARP 
trial, Llovet et al. studied a huge population of patients 
with advanced HCC. Data showed that any grade 
hypertension was present in 5% of patients (among the 
297 patients in the sorafenib-arm), among them 2% had 
grade 3 hypertension, while no grade 4 hypertension was 
registered. Cardiac ischemia or infarction was revealed 
in 3% of patients. To achieve regulatory approval also in 
China, sorafenib had to be examined, in a parallel study, in 
about 200 patients with HCC from the Asia-Pacific region. 
This study highlighted that all grade hypertension was 
present in 18.8% (twenty-eight patients) and among them 
2% had grade 3 or 4 hypertension. The incidence of heart 
attack or cardiac ischemia occurring during treatment in 
sorafenib-treated patients was 2.7% [9, 20-22].
Sorafenib was firstly studied in advanced RCC in 
the TARGET trial. 451 patients were assigned to receive 
continuous treatment with sorafenib and compared to the 
placebo-arm. In this study twenty-two patients (4.9%) 
were assigned to the sorafenib-arm. They reported cardiac 
ischemia/infarction and six events were correlated to the 
investigational drug. Among these patients one cardiac 
ischemic event led to permanent discontinuation of 
study drug. All grade hypertension was reported in 17% 
(seventy-eight patients), of which 4% had grade 3 or 4 
hypertension. A larger population was then studied in 
North America through an expanded access program, in 
which about 2.504 patients were enrolled. The incidence 
of all-grade hypertension was 12%, and 5% was grade 
3 hypertension. Schmidinger et al. in an observational, 
single-center study, evaluated cardiac toxicity in eighty-six 
patients affected by metastatic RCC. These patients were 
treated with either Sunitinib or Sorafenib. Among these 
patients only seventy-four of them were eligible for the 
study, 33.8% among them experienced a cardiac event (25 
patients), 40.5% had ECG changes (30 patients, of which 
12 experienced a cardiac event while 18 did not experience 
a cardiac event) and 18% were symptomatic (13 patients). 
However these valuations included both treatments. 
Giving a closer look to the Sorafenib-treated patients, 
it is possible to highlight that 14 patients experienced a 
cardiovascular event (56% upon the whole of 25 patients). 
Besides, among these 14 patients, six patients had ECG 
changes. Eight patients had symptoms likely related to 
myocardial damage. Furthermore, the use of Sorafenib led 
to cardiac ischemia in 3% of patients [9, 23-25].
The recent prospective, open-label, non-
interventional, non-controlled, multicenter study 
conducted in 18 countries, which is called PREDICT 
study, enrolled 2855 patients with advanced RCC. All of 
them were treated with Sorafenib. It registered, among the 
drug-related adverse events, only hypertension, which was 
present in 4.2% (110 patients) [26].
It is more recent the phase 3 trial, which led to the 
approval of Sorafenib in locally advanced or metastatic 
differentiated thyroid cancer. The DECISION trial is a 
multicentre, randomised, double-blind, placebo-controlled 
study, in which patients were assigned on a 1:1 basis to 
Sorafenib or placebo, so 207 patients were randomised in 
the Sorafenib-arm. Any grade hypertension was present 
in 40.6% (84 patients), of which 9.7% was grade 3 (20 
patients), while no grade 4 hypertension was registered. 
As regards dyspnoea, any grade was highlighted in 14.5% 
(30 patients), grade 3 in 4.8% (10 patients). No grade 4 
dyspnoea was registered. Among serious adverse events 
occurring in 2% or more of patients receiving Sorafenib, 
there was dyspnoea in 3.4% (7 patients among 207). 
One death, in the Sorafenib group, was attributable to 
myocardial infarction [27].
Many other studies evaluated the safety profile of 
Sorafenib compared to either placebo or another drug 
(including sunitinib, axitinib, brivanib, tivozanib, dovitinib 
and linifanib). All the studies reported hypertension, all 
grade hypertension ranging from 17.5% to 34% (with a 
mean value of about 26%). More heterogeneous values 
were recorded as regards grade 3/4 hypertension ranging 
from 1% to 18% (with a mean value of about 10%). Most 
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of these studies registered asthenia, all grade asthenia 
ranging from 11.4% to 17% (mean value of about 14%) 
and grade 3/4 asthenia ranging from 2.1% to 5% (mean 
value of about 3.5%). Very few cases led to discontinuation 
of treatment with Sorafenib. The studies also reported 
other cardiovascular adverse events that were present in 
low percentage or in individual cases, such as myocardial 
ischemia, cardiac failure, pulmonary embolism, peripheral 
edema and cerebrovascular accidents. Two studies 
reported dyspnoea but they registered very different 
percentages. One of them reported all grade dyspnoea in 
9% of patients of which 2% had grade 3/4. The other one 
reported all grade dyspnoea in 20% of patients, of which 
7% had grade 3/4 [28-36].
Similar results about hypertension were observed 
in a meta-analysis by Funakoshi T et al. All grade 
hypertension was present in 23.1% of patients. High-grade 
hypertension occurred in 6.0% [37].
Another meta-analysis by Choueiri et al. evaluated 
the incidence and the risk of arterial thromboembolic 
events (ATEs) linked to Sorafenib. ATEs had an incidence 
by 1.7%, while it was calculated an RR of ATE by 3.1 
[38].
In a phase 1 open-label study Tolcher et al. analysed 
the cardiovascular safety of Sorafenib. They evaluated 
the baseline and the variations of QTc interval, together 
with other parameters such as left ventricular ejection 
fraction (LVEF), blood pressure and heart rate. Thirty-
one patients, after one cycle of Sorafenib treatment, 
showed a modest prolongation of the QT/QTc interval. 
They registered mean increases from baseline by 9.0 and 
4.2 milliseconds (ms) respectively for QTcF and QTcB. 
None of the patients had a QTcB or QTcF value >500 ms 
at any time of the study. Besides none of them showed 
a change from baseline in QTcB or QTcF ≥60 ms. Only 
one patient had a prolongation in either QTcB or QTcF 
that was a +50 ms change from QTcF baseline. Besides, 
this study highlights that there are few cases in which the 
mean maximal increases from baseline can be of 16 ms for 
QTcB and 20 ms for QTcF. This was showed in continuous 
treatment with Sorafenib. So these results reveal that there 
is no clinically relevant effect of Sorafenib on cardiac 
repolarization, if it is used at therapeutic doses (400 mg 
BID) [39].
Sorafenib was firstly created to inhibit RAF kinases. 
It strongly acts on Raf-1 and BRAF more than the other 
targets it has. This could be underlined taking a look to 
the IC50 it has towards its targets. IC50 is the half maximal 
inhibitory concentration at which the compound reaches 
half of its maximal inhibitory effect. Raf-1 is affected with 
a mean IC50 of 6 nM with a standard deviation (SD) of ± 3; 
BRAF wild-type: 25 ± 6; its mutant form BRAFV600E: 38 
± 9; VEGFR-2: 90 ± 15; murineVEGFR-2 (flk-1): 15 ± 6; 
mVEGFR-3: 20 ± 6; mPDGFR-β: 57 ± 20; Flt-3: 58 ± 20; 
c-KIT 68 ± 21. A study evaluated the interaction between 
several kinases and thirty-eight kinase inhibitors. In this 
study Sorafenib strongly bound to 38% of the tyrosine and 
11% of the serine/threonine kinases. The kinase binding 
dissociation constant (Kd - which is commonly used to 
describe the affinity between a ligand and a protein) was 
less than 3 μM. This concentration is under therapeutic 
plasma levels. Besides, only 16% of the tyrosine kinases 
and 1% of the serine/threonine kinases bound Sorafenib 
with a Kd of less than 100 nM. This is the value under 
which there is a greater binding affinity between the drug 
molecule and the ligand. In fact, the lower the value of 
Kd is the higher the binding affinity will be, and vice 
versa. So, even though sorafenib was initially described 
as a potent inhibitor of RAF serine/threonine kinase, it 
preferably binds tyrosine kinases and in some cases with 
affinities within ten-fold of that for its expected primary 
target [40-42].
Regorafenib
The kinase inhibitor Regorafenib has been approved 
for the treatment of patients affected by metastatic 
colorectal cancer (CRC). Patients already treated with 
fluoropyrimidine-, oxaliplatin- and irinotecan-based 
chemotherapy, an anti-VEGF therapy, and also an anti-
EGFR therapy, if the patients have a wild type KRAS 
mutational status. It has also been approved for locally 
advanced, unresectable or metastatic gastrointestinal 
stromal tumors (GIST) in patients who have been 
previously treated with imatinib mesylate and sunitinib 
malate. Regorafenib is a small molecule. It inhibits several 
membrane-bound and intracellular kinases involved both 
in normal cellular functions and in pathologic processes 
such as oncogenesis, tumor angiogenesis, and maintenance 
of the tumor microenvironment. It suppresses the action 
of several targets such as RET, VEGFR-1, VEGFR-2, 
VEGFR-3, KIT, PDGFR-α, PDGFR-β, FGFR-1, FGFR-2, 
TIE2, DDR2, TrkA, Eph2A, Raf-1, BRAF and its mutant 
form BRAFV600E, SAPK2, PTK5, and Abl [43-45].
There are two main phase 3 trials that led to the 
approval of regorafenib by the FDA. The CORRECT 
trial studied patients affected by metastatic CRC. The 
GRID trial studied patients affected by advanced GIST. 
In the CORRECT trial, among the 500 patients treated by 
regorafenib, the most present cardiovascular side effect 
was hypertension. Any grade hypertension emerged in 
28% of the patients, grade 3 hypertension emerged in 
7% of the patients, while no grade 4 hypertension was 
highlighted. The other cardiovascular side effect, which 
came to light, was dyspnoea. Any grade dyspnoea was 
present in 6% of patients (28 patients) including only 
one patient experiencing grade 3 dyspnoea (< 1%). No 
grade 4 dyspnoea was reported. Among patients assigned 
to regorafenib-arm, 12 patients (2%) had thromboembolic 
events. Besides, regorafenib increased the incidence of 
myocardial ischemia and infarction 1.2% versus 0.4% 
in the placebo-arm. In the GRID trial, 132 patients were 
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treated with regorafenib. Among them 48.5% had any 
grade hypertension (64 patients), 22.7% presented grade 3 
hypertension (30 patients), while only one patient (0.8%) 
had grade 4 hypertension. So, among grade ≥3 side effects, 
hypertension was the most common (23.5%). This adverse 
event could be managed with dose modification and 
appropriate anti-hypertensive intervention. One patient, 
in the regorafenib-arm, had cardiac arrest, which was 
considered by the investigators a grade 5 adverse event 
drug-related [9, 46-48].
Regorafenib has also been studied for advanced 
HCC in a phase 2 trial. It reported any grade hypertension 
in 36% of the patients (13 patients), of which one patient 
(3%) had grade ≥3 hypertension. One patient (3%) had 
grade ≥3 arrhythmia, which led to discontinuation of 
treatment[49, 50].
In an open label, single arm study, 25 patients with 
advanced solid tumors assumed regorafenib at multiple 
doses. In this study the effect of multiple doses on the QTc 
interval was evaluated. No large changes in the mean QTc 
interval (> 20 msec) were detected in the study.
Regorafenib is biochemically similar to sorafenib 
but essentially different, by showing a more powerful 
inhibition on oncogenic kinases. This aspect emerges 
from its biochemical profile, namely the IC50 on each 
target kinase. VEGFR-1 has an IC50 of 13 nM with a SD 
of ± 0.4, murineVEGFR-2: 4.2 ±1.6, murineVEGFR-3:46 
± 10, TIE2: 311 ± 46, PDGFR-β: 22 ± 3, FGFR-1: 
202 ± 18, KIT: 7 ± 2, RET: 1.5 ± 0.7, Raf-1: 2.5 ± 0.6, 
B-RAFwt: 28 ± 10, BRAFV600E: 19 ± 6. These target 
kinases were also analyzed in mechanistic cellular 
phosphorylation assays. They evaluated the inhibition of 
receptor auto-phosphorylation in cells, which expressed 
FGFR, PDGFR-β, BRAF, VEGFR-2, VEGFR-3, TIE2. 
Regorafenib potently inhibited VEGFR-2 and TIE2 auto-
phosphorylation in cells with an IC50 respectively by 3 nM 
and 31 nM. It inhibited PDGFR-β auto-phosphorylation 
with an IC50 of 90 nM, while FGFR signalling with a value 
of about 200 nM. Finally, the inhibition of the MAPK 
signalling pathway was evaluated using tumor cells, which 
expressed wild-type KRAS and BRAF, and in melanoma 
cell line BRAFV600E mutated. The first ones had an IC50 by 
380 nM, while the second ones had an IC50 by 272 nM. 
So, the potency of inhibition from regorafenib expressed 
in the cellular assays was correlated to the one showed in 
biochemical assays, with some exceptions. TIE2 showed 
an inhibition of about 10-fold weaker in biochemical 
assays than the cellular auto-phosphorylation assay. On the 
contrary, BRAF and BRAFV600E highlighted an inhibition 
of about 14-fold stronger in biochemical assays than the 
cellular auto-phosphorylation assay [51, 52].
Vemurafenib
Vemurafenib is a kinase inhibitor. It has been 
approved for the treatment of patients with unresectable 
or metastatic melanoma with BRAFV600E mutation. It is 
an orally administered drug, which potently inhibits some 
BRAF serine-threonine kinases with activating mutations 
and in particular BRAFV600E. Besides, vemurafenib has 
shown in vitro inhibitory activity on other kinases such as 
CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5 
and FGR[55-57]. Vemurafenib inhibits BRAFV600E with an 
IC50 of 31 nM, 48 nM for CRAF, 100 nM for wild-type 
BRAF. It inhibits SRMS with an IC50 of 18 nM, 19 nM 
for ACK1, 51 nM for MAP4K5 and 63 nM for FGR [55]. 
Three studies represent the cornerstone in the 
approval of vemurafenib by the FDA. These are BRIM-
1 (phase 1 trial), BRIM-2 (phase 2 trial) and most 
importantly the BRIM-3 (phase 3 trial). In the BRIM-3 
trial, vemurafenib was compared to dacarbazine in 675 
patients with previously untreated metastatic melanoma 
BRAFV600E-mutated. In this study there were four deaths 
(1%) in patients treated by vemurafenib not directly 
attributed to disease progression, which occurred 
Table 2: Mean all grades of each side effect linked to cardiotoxicity of the BRAF inhibitors.
Drug
Side effect
(mean all grades)
Hypertension
Cardiac 
ischemia / 
Infarction
Arterial thrombo-
embolic events
QT prolongation / 
ECG changes
CHF and/or symptoms 
related (e.g. Asthenia, 
Dyspnea, Peripheral 
edema)
Sorafenib ~ 22.6 % ~ 2.5 % ~ 1.7 % ~ 8.1 % ~ 14.5 %
Vemurafenib 6 % ------ ------ ~ 8.5 % ~ 8.8 %
Regorafenib ~ 37.5 % ~ 1.2 % ~ 2 % No clinically significant effect 6 %
Dabrafenib ------ ------ ------ ------ ------
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within 28 days from the last dose administration of the 
investigational drug. These deaths were linked to fatal 
adverse events, which were cerebrovascular accident, 
pneumonia, cardiopulmonary failure and aortic aneurysm 
rupture. But, none of them were attributed to vemurafenib. 
Grade 1-4 asthenia was recorded in 36 patients in 
vemurafenib-arm (10.7%). The QT interval was examined 
in a sub-study within BRIM-2, showing that for this drug 
there is a concentration-dependent increase in QT interval 
[54, 56, 57].
In the Expanded Access Program conducted in the 
United States patients with metastatic melanoma were 
treated with vemurafenib. Among these patients twenty-
four (7%) had an increase in QTc interval of more than 
480 milliseconds. Eleven patients (3%) had QTc intervals 
of more than 500 milliseconds. Nineteen patients (5%) got 
an increase in QTc interval from baseline by at least 60 
milliseconds. But, it has to be noted that none of these QTc 
interval prolongations was associated with any significant 
clinical finding, such as arrhythmia. Two patients reported 
a prolonged QT interval, which was a treatment-related 
serious adverse event. Besides in two cases (0.5%) the 
prolonged QT interval led to vemurafenib permanent 
discontinuation [58].
Larkin et al. studied in an open-label, multicentre, 
safety study, 3222 patients with BRAFV600 mutated 
metastatic melanoma, who received at least one dose of 
vemurafenib. Among these patients 316 (overall - 10%) 
experienced prolonged QT interval with or without clinical 
manifestation, such as atrial fibrillation, sinus tachycardia, 
atrial flutter and other atrial arrhythmias, and ventricular 
arrhythmias. Grade 1 and 2 QT prolongation was present 
in 287 patients (9%), while 52 patients (2%) had corrected 
(Fridericia) QT interval (QTcF) prolongation of more than 
500 ms (grade 3 and 4). Peripheral edema was present in 
215 patients (7%), including 212 with grade 1 and 2, while 
5 had grade 3 and 4. Hypertension was also registered, 
Grade 1 and 2 in 117 patients (4%), while grade 3 and 4 in 
76 (2%) with an overall percentage by 6%. Four patients 
died because of cerebrovascular accident and other four 
patients died because of pulmonary embolism. The most 
common adverse event leading to drug discontinuation 
included QTc prolongation in nine patients (<1%). 
Among these ones only two had QTcF longer than 500 
ms, dyspnoea in six (<1%) and cerebral haemorrhage in 
six (<1%) [59].
More recently Larkin et al. evaluated the efficacy 
of the combination therapy with vemurafenib and 
cobimetinib in comparison with vemurafenib plus placebo. 
Among the 239 patients treated with vemurafenib plus 
placebo grade 1 QT-interval prolongation was registered 
in 8 patients (3%), grade 2 in 2 (1%), grade 3 in 3 (1%); 
no grade 4 toxicity was registered. Low percentage 
of frequency was also reported for decreased ejection 
fraction, there was no grade 1 or 4 toxicity, grade 2 was 
present in 4 patients (2%), while grade 3 was present in 3 
(1%) [60].
Besides, some medical cases report cardiovascular 
toxicity by vemurafenib. They report about not only QT-
interval prolongation, but also about pericarditis and some 
of them with effusion and tamponade [61, 62].
Dabrafenib
Dabrafenib is a potent and selective inhibitor 
of some mutated forms of BRAF kinases. It has been 
approved as a single agent or in combination with 
trametinib for the treatment of patients with unresectable 
or metastatic melanoma with BRAFV600E mutation (and 
also metastatic melanoma with BRAFV600K mutation for 
the combination therapy). It is not indicated for treatment 
of patients with wild-type BRAF melanoma. It inhibits in 
vitro and in vivo BRAF mutated forms with an IC50 by 0.65 
nM for BRAFV600E, 0.5 nM for BRAFV600K, 1.84 nM for 
BRAFV600D. Less potently it inhibits CRAF with an IC50 
of 5.0 nM and wild-type BRAF kinases with an IC50 of 
3.2 nM and at greater concentrations other kinases such as 
SIK1, NEK11, and LIMK1[63].
The clinical trials, which led to the approval of this 
drug by the FDA are called BREAK. They are BREAK-1 
(phase 1 trial), BREAK-2 (phase 2 trial), BREAK-3 
(phase 3 trial) and BREAK-MB (phase 2 trial in BRAF-
mutant melanoma metastatic to the brain). No significant 
cardiovascular toxicity was reported in these trials, in 
which patients were treated with dabrafenib as a single 
agent [64-67].
Cardiovascular adverse events were recorded 
in patients which underwent the combination therapy 
dabrafenib plus trametinib. These adverse events were 
venous thromboembolism, decreased ejection fraction, 
pulmonary embolism, cardiomyopathy, hypertension 
and hypotension, which were present in low percentages. 
But, it is not possible to determine which one of the 
two drugs is more cardiotoxic than the other one or 
if it is the combination therapy itself that determines 
cardiotoxicity[68-70].
Drugs in development
Many other molecules are still in development. 
Most of them are so far studied in preclinical level, while 
others have reached phase 1 trials. So, they still need more 
data in order to establish if they determine cardiotoxicity 
and eventually which level of expression. They include 
RAF265, an orally bioavailable small molecule. It inhibits 
the activities of several intracellular kinases such as 
BRAFV600E, wild-type BRAF, CRAF, VEGFR2, PDGFR, 
RET, c-KIT, SRC and other targets with an IC50 ranging 
from less than 20 to more than 100 nM. It inhibits more 
potently BRAFV600E and VEGFR2 than the other targets. 
Among these molecules there are also PLX-8394, TAK-
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632 (which is a potent and selective pan-RAF inhibitor 
that overcomes paradoxical RAF activation), MLN-2480. 
The molecule PLX-4720 was one of the first highly 
selective inhibitors of mutant BRAFV600E (IC50 = 13 nM). It 
was effective on cell lines in preclinical studies, but it did 
not reach in vivo pharmacologic levels to affect efficiently 
BRAFV600E [16, 71-77].
Finally, LGX818 a highly potent BRAF inhibitor has 
been studied and developed for BRAF-mutated advanced 
melanoma. It has a much longer half-life of dissociation 
from BRAFV600E kinase than the other molecules. It 
emerged from the studies that its toxicity profile was 
similar to those of vemurafenib and dabrafenib. At 
present, there is an ongoing trial. The COLUMBUS trial 
is a randomized, open label, 3-arm phase 3 study which 
compares the efficacy and safety of LGX818-MEK162 
combination or LGX818 monotherapy to vemurafenib in 
patients with unresectable or metastatic melanoma with 
BRAFV600 mutation (NCT01909453) [78].
HYPOTHESES FOR ANTI-BRAF-RELATED 
CARDIOTOXICITY
The human ether-a-go-go related-gene K+ channel 
hERG is encoded by the KCNH2 gene. It is a voltage-
activated K+ channel responding to changes in membrane 
potential, widely expressed in the heart. It has a critical 
role in the repolarization process of the action potential 
in cardiomyocytes. In fact, these channels are responsible 
of the rapidly activating delayed rectifier K+ current (IKr) 
in the heart. The outward K+ currents and in particular the 
delayed rectifier repolarizing current IK correlates with 
repolarization. This determines the configuration of the 
action potential. It results from the sum of two different 
types of K+ currents: the rapid component, IKr, and the 
slow component, IKs. These currents are fundamental in the 
transition from phase 2 to phase 3 of the action potential 
in cardiomyocytes. So, small changes in conductance can 
significantly modify the effective refractory period, hence 
the action potential duration. A reduction or an increase 
in IKr lead respectively to long or short QT interval 
converting in a QT syndrome. So, both of these conditions 
render liable affected hearts to fatal arrhythmias (including 
torsades de pointes, TdP) and sudden cardiac death. 
The hERG channels could be also up-regulated by the 
signalling of growth factors and contribute to it. Among 
these factors there is BRAF, which may participate in the 
regulation of these channels. Cardiac cells express all the 
three RAF family members, RAF-1, BRAF, and ARAF. 
They stimulate survival and growth of cardiomyocytes. A 
recent study has shown that BRAF is a powerful regulator 
of hERG K+ channels, stimulating them. Wild-type BRAF 
increased hERG channel protein abundance in the cell 
membrane and consequently it increased the hERG-
mediated current through the cell membrane. Furthermore, 
cells treated with the BRAF inhibitor PLX-4720 
highlighted a down-regulation of hERG channel protein 
quantity and activity. Hence, it is possible to consider that 
BRAF inhibitors down-regulating hERG channels protein 
quantity and down-regulating their activity, undermine 
IKr. This event determines a slowdown in repolarization, 
which leads lastly to QT prolongation [79-84].
It remains to understand the mechanism by which 
BRAF acts on hERG channels. Studies revealed that in 
some cells cAMP stimulates MAPK activation in the 
presence of BRAF and Rap1. In fact, cAMP activation 
stimulated PKA, which in turn activated BRAF through 
the small G protein Rap-1. The latter is a selective activator 
of BRAF and inhibitor of Raf-1. Other studies disclosed 
that increased concentration of cAMP determines effects 
on hERG function through two pathways. Although 
it increases hERG protein abundance and the channel 
production, it decreases the trafficking velocity. On 
one hand, cAMP stimulates PKA. The latter directly 
phosphorylates hERG. PKA-dependent phosphorylation 
of hERG gives the channels a minor ability to open 
during action-potential voltages. So, there is an inhibition 
of K+ current directed towards the outside of the cell at 
all voltages. On the other hand, cAMP directly binds to 
the hERG protein and shifts the voltage-dependence of 
activation to depolarized potentials. Even though this 
direct effect counterweights the PKA-dependent action, 
the current inhibition and accelerated deactivation remain 
unopposed. The final effect is a reduction of hERG 
current. So, it could be possible to hypothesize that BRAF 
inhibition through an inhibitory molecule determines a 
compensatory up-regulation of cAMP. The increase in 
cAMP concentration leads to the stimulation of PKA, 
whose action stimulates the phosphorylation of hERG 
channels. This event gives the channels a minor capability 
to open and facilitate the repolarization of the cell. The 
slowdown of the repolarization implies QT prolongation 
[85-90] (Figure 1).
CONCLUSIONS
The RAS/RAF/MEK/ERK pathway has a central 
role in many cellular processes. It transmits a mitogenic 
signal and stimulates cell proliferation, gene expression 
and survival. The molecules involved in this pathway have 
been investigated for many years either in their wild-type 
or mutated form. The evidence of BRAF mutated forms 
(above all BRAFV600E) in melanoma, papillary thyroid 
cancer and colorectal cancer have pushed the researchers 
to focus on this target. Over time various molecules 
have been developed, first as multi-target agents but 
progressively the aim has become to produce drugs that 
could selectively target BRAF and particularly its mutated 
forms. These selective molecules for BRAF mutated 
forms have shown to impair QT interval throughout their 
development. For this reason a precaution for the use of 
BRAF inhibitors in patients with pre-existing conditions 
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affecting their QT interval on ECG has been inserted in 
their label.
In this work we analyze the cardiotoxicity data 
related to molecules that target either as multi-target or 
selective agents (Table 2). The data analysis shows that 
multi-target molecules have somewhat an influence 
on QT interval, even though clinically not significant. 
Vemurafenib, as a selective agent, has a more consistent 
influence on QT interval leading to clinically significant 
changes. Conversely the recently approved BRAF 
inhibitor dabrafenib seems to have a slight cardiotoxic 
effect when used in combination with trametinib. Such 
heterogeneity of data can be a consequence of the different 
power by which each molecule hits its target in vivo 
compared to that one disclosed in vitro.
Herein we propose a mechanism through which 
BRAF inhibitors may determine their cardiotoxic effect. 
Indeed we hypothesize that BRAF inhibitors blocking 
this molecule lead to an increase in cAMP activity and 
through PKA, this event increases hERG channels 
phosphorylation. These channels normally facilitate 
K+ ions transit, which correlates with myocardial 
repolarization process. Phosphorylation decreases the 
function of these channels. Certainly many molecules 
could intervene in this mechanism. Some data about the 
association of Raf-1 with cardiovascular adverse events 
are reported in literature [91, 92].
Although the cardiac effects of BRAF inhibitors 
in clinical trials are reported in low percentage, attention 
must be paid on the use of these drugs, because an 
uncontrolled QT prolongation could expose to a syndrome 
that would lead to fatal arrhythmias and sudden cardiac 
death.
Therefore a cooperation between Oncologists and 
Cardiologists is very important when these drugs are 
delivered. While Oncologists should pay attention to 
the potential onset of these effects, Cardiologists should 
promptly and appropriately treat as necessary the side 
effects that occur. The rising integrated discipline called 
Cardio-Oncology should focus on research about BRAF 
inhibitors, either developing experimental models on 
cardiotoxicity and planning prospective studies focused 
on the cardiac effects of these drugs.
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